清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

医学 安慰剂 杜皮鲁玛 嗜酸性食管炎 吞咽困难 内科学 随机对照试验 兰索拉唑 胃肠病学 儿科 外科 奥美拉唑 疾病 哮喘 病理 替代医学
作者
Marc E. Rothenberg,Evan S. Dellon,Margaret H. Collins,Ikuo Hirano,Mirna Chehade,Albert Jan Bredenoord,Alfredo José Lucendo,Jonathan M. Spergel,Xian Sun,Jennifer D. Hamilton,Eric R. Mortensen,Elizabeth Laws,Jennifer M. Maloney,Leda Mannent,Eilish McCann,Xia Liu,Lila Glotfelty,Arsalan Shabbir
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:8 (11): 990-1004 被引量:139
标识
DOI:10.1016/s2468-1253(23)00204-2
摘要

Long-term management options that specifically target the underlying inflammation in eosinophilic oesophagitis are needed. Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13; we aimed to assess its long-term efficacy and safety in adults and adolescents with eosinophilic oesophagitis enrolled in part B of the LIBERTY EoE TREET study who continued to part C (part B-C).LIBERTY EoE TREET was a three-part, double-blind, randomised, placebo-controlled, phase 3 study conducted at 65 hospitals and private clinics across ten countries in Australia, Canada, Europe, and the USA. Adults or adolescents (aged ≥12 years) with a diagnosis of eosinophilic oesophagitis by endoscopic biopsy (peak oesophageal intraepithelial eosinophil count ≥15 eosinophils per high-power field [eos/hpf]) from at least one oesophageal region despite 8 weeks of high-dose proton-pump inhibitors (PPIs) and a Dysphagia Symptom Questionnaire (DSQ) score of at least 10 at baseline were eligible. In part B, patients were randomly (1:1:1) assigned to receive subcutaneous dupilumab 300 mg either weekly or every 2 weeks or weekly placebo until week 24. Randomisation was done centrally by interactive voice response system/web response system (IVRS/IWRS) in blocks and stratified according to age (<18 years vs ≥18 years) and use of PPI at randomisation (yes vs no). Patients, study sponsors, and investigators involved in the study were masked to the randomisation outcome. Eligible patients who received placebo in part B and continued to part C were randomly assigned again (1:1) to either weekly dupilumab (placebo/weekly dupilumab group) or dupilumab every 2 weeks (placebo/dupilumab every 2 weeks), with matching placebo alternating with dupilumab doses. Patients who were randomly assigned to one of the dupilumab dose regimens in part B remained on the same regimen in part C for an additional 28 weeks (weekly dupilumab/weekly dupilumab group or dupilumab every 2 weeks/dupilumab every 2 weeks group). Treatment assignment in part C was managed by IVRS/IWRS to maintain blinding of treatment assignment in part B. The primary endpoint of this trial has been reported; here, we report the week 52 outcomes of part B-C. Efficacy and safety analyses were done in the part C safety-analysis set, which included all patients who were randomised in part B, entered part C, and received any study drug in part C. This completed trial is registered with ClinicalTrials.gov, number NCT03633617.Between Aug 12, 2019, and March 11, 2021, 240 patients were randomly assigned into part B, of whom 227 (74 in placebo group, 74 in weekly dupilumab group, and 79 in dupilumab every 2 weeks group) continued into part B-C and were included in the current analysis. 37 patients switched from placebo to weekly dupilumab, and 37 from placebo to dupilumab every 2 weeks; 74 patients continued on weekly dupilumab and 79 continued on dupilumab every 2 weeks. Of the patients who entered part B-C, 75 (33%) were adolescents, 145 (64%) male, 82 (36%) female, and 206 (91%) White. At week 52, 55 (85%) patients in the weekly dupilumab/weekly dupilumab group, 25 (68%) in the placebo/weekly dupilumab group, 54 (74%) in the every 2 weeks dupilumab/every 2 weeks dupilumab group, and 23 (72%) in the placebo/every 2 weeks dupilumab group achieved a peak oesophageal intraepithelial eosinophil count of 6 eos/hpf or less. Mean percent change from part B baseline in peak eosinophil count was -95·9% (95% CI -96·9 to -94·9) in the weekly dupilumab/weekly dupilumab group, -84·2% (-98·3 to -70·2) in the placebo/weekly dupilumab group, -84·8% (-94·3 to -75·2) in the every 2 weeks dupilumab/every 2 weeks dupilumab group, and -91·2% (-95·9 to -86·5) in the placebo/every 2 weeks dupilumab group at week 52. At week 52, mean change from part B baseline in eosinophilic oesophagitis Histology Scoring System (HSS) grade score was -1·0 point (95% CI -1·1 to -0·9) in the weekly dupilumab/weekly dupilumab group and -0·9 points (-1·0 to -0·8) in the placebo/weekly dupilumab group; mean change in eosinophilic oesophagitis HSS stage score was -0·9 points (-1·0 to -0·8) in the weekly dupilumab/weekly dupilumab group and -0·9 points (-1·0 to -0·8) in the placebo/weekly dupilumab group. Similar improvements were observed in the every 2 weeks dupilumab groups. Mean absolute change from part B baseline in DSQ score was -30·3 points (95% CI -34·5 to -26·1) in the weekly dupilumab/weekly dupilumab group, -27·3 points (-32·1 to -22·4) in the placebo/weekly dupilumab group, -20·9% (-25·4 to -16·3) in the every 2 weeks dupilumab/every 2 weeks dupilumab group, and -23·7% (-29·1 to -18·3) in the placebo/every 2 weeks dupilumab group at week 52. Mean change from part B baseline in endoscopic reference score was -5·4 points (95% CI -6·1 to -4·6) in the weekly dupilumab/weekly dupilumab group, -6·1 points (-7·3 to -4·9) in the placebo/weekly dupilumab group, -5·2% (-6·0 to -4·4) in the every 2 weeks dupilumab/every 2 weeks dupilumab group, and -4·3% (-5·4 to -3·1) in the placebo/every 2 weeks dupilumab group at week 52. During part B-C, one (3%) patient in the placebo/weekly dupilumab group, one (1%) in the weekly dupilumab/weekly dupilumab group, and one (3%) in the placebo/every 2 weeks dupilumab group received rescue medication. One (3%) patient in the placebo/every 2 weeks dupilumab group and one (1%) in the dupilumab every 2 weeks/dupilumab every 2 weeks group underwent a rescue oesophageal dilation procedure. The most common treatment-emergent adverse events were injection-site reactions (ten [14%] in the weekly dupilumab/weekly dupilumab group and four [11%] in the placebo/weekly dupilumab group).Improvements in histological, symptomatic, endoscopic, and molecular features of eosinophilic oesophagitis observed after 24 weeks of weekly dupilumab treatment were maintained or continued to improve to week 52. These findings reinforce the importance of weekly dupilumab, rather than every 2 weeks, for the improvement of symptoms in adults and adolescents with eosinophilic oesophagitis.Sanofi and Regeneron Pharmaceuticals Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风中睫毛完成签到,获得积分10
18秒前
冷酷的易文完成签到,获得积分10
34秒前
molihuakai的应助被科研通管家采纳,获得10
48秒前
Khan完成签到,获得积分10
49秒前
天天快乐的应助被Wang采纳,获得10
53秒前
公子小白完成签到,获得积分10
58秒前
迷路牛青完成签到,获得积分10
1分钟前
limengyao完成签到,获得积分10
1分钟前
温柔晓筠完成签到,获得积分10
1分钟前
落后的雪青完成签到,获得积分10
1分钟前
Aman完成签到,获得积分10
1分钟前
精明开山完成签到,获得积分10
1分钟前
1分钟前
Wang发布了新的文献求助10
1分钟前
安静怜雪完成签到,获得积分10
2分钟前
火柴盒完成签到,获得积分10
2分钟前
隐形雅柔完成签到,获得积分10
2分钟前
dnpl完成签到,获得积分10
2分钟前
潇洒醉冬完成签到,获得积分10
2分钟前
Aman完成签到,获得积分10
2分钟前
Aman完成签到,获得积分10
2分钟前
细心的语蓉完成签到,获得积分10
2分钟前
车车完成签到 ,获得积分10
2分钟前
追寻的凌香完成签到,获得积分10
2分钟前
2分钟前
Maestro_S的应助被科研通管家采纳,获得10
2分钟前
调皮烤鸡完成签到,获得积分10
2分钟前
能干的孱完成签到,获得积分10
2分钟前
小巧的大凄完成签到,获得积分10
3分钟前
3分钟前
古炮完成签到 ,获得积分10
3分钟前
又何必呢完成签到 ,获得积分10
3分钟前
英俊的青烟完成签到,获得积分10
3分钟前
TingtingGZ发布了新的文献求助10
3分钟前
沉默怡完成签到,获得积分10
3分钟前
田田完成签到 ,获得积分10
3分钟前
奔跑的应助被武雨寒采纳,获得10
4分钟前
梁吃鱼完成签到 ,获得积分10
4分钟前
无悔完成签到 ,获得积分0
4分钟前
内向的小丸子完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173213
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780496
捐赠科研通 7767342
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476697